Friday 6 November 2026 Export MDGL’s income statement to Excel — free account

Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $958.4 million, up 432.1% from fiscal 2024.

Revenue: +50.1%
EPS: +147.3%
Free cash flow: +53.5%
Total debt: +0.45%

Quarter to September 2026, against a year earlier

395.13 4.97 −1.24%

Follow MDGL

Alert me

Market cap: $9.3B
P/E: 0.0×
Fwd P/E: −68.8×
Dividend yield: —
F-score: n/a
Altman Z: 10.48
Beneish M: 0.50
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Madrigal Pharmaceuticals, Inc. 10-Q filed Jul 30, 2026

Fiscal Q2 2026 · Period ended Jun 30, 2026 · Filed Jul 30, 2026 · accepted 9:06 AM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis Part II, Item 1A, Risk Factors

Previous quarter Same quarter last year

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Aug 5, 2025: 39 added · 29 removed · 43 modified; 5 with only figures updated

Madrigal Pharmaceuticals, Inc. 10-Q filed Jul 30, 2026

What changed

Stockrow Weekly